Concepedia

Author

Paul‐Egbert Reimitz

Daiichi Sankyo (Germany)ORCID

Also Known As

Michael Kerschnitzki, P E Reimitz, P Reimitz, P. -E. Reimitz, P. E. REIMITZ, P. E. Reimitz, P. Reimitz, P.-E Reimitz, P.-E. Reimitz, P.E Reimitz

57

Publications

2K

Citations

17

H-Index

40

Concepts

All Affiliations

Daiichi Sankyo (Germany)University of MünsterUniversity of AmsterdamUniversity of BirminghamAtrial Fibrillation NETwork
PR

About

Paul‐Egbert Reimitz is an author at Daiichi Sankyo (Germany) specializing in medicine, psychiatry, and pharmacotherapy.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

8

8

1.4K

2

Social Sciences

5

5

613

3

Pharmacology

5

5

976

4

Public Health

3

3

819

5

Neurology

1

1

168

Paul‐Egbert Reimitz

×

17

Publications

1.8K

Citations

15

H-Index

YearCitations

Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial

Pascal Vranckx, Marco Valgimigli, Lars Eckardt,

The Lancet

2019

636

The Inventory of Depressive Symptomatology (IDS): Clinician (IDS‐C) and Self‐Report (IDS‐SR) ratings of depressive symptoms

A. John Rush, Thomas Carmody, Paul‐Egbert Reimitz

International Journal of Methods in Psychiatric Research

2000

430

Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial

Stefan H. Hohnloser, A. John Camm, Riccardo Cappato,

European Heart Journal

2019

168

Mirtazapine versus amitriptyline in the long-term treatment of depression

Stuart Montgomery, Paul‐Egbert Reimitz, M. Zivkov

International Clinical Psychopharmacology

1998

121

Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: Rationale and design of the ENTRUST-AF PCI trial

Pascal Vranckx, Thorsten Lewalter, Marco Valgimigli,

American Heart Journal

2017

86

Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: 1-year follow-up of the prospective observational ETNA-AF-Europe study

Joris R. de Groot, Thomas W. Weiss, Peter J. Kelly,

European Heart Journal - Cardiovascular Pharmacotherapy

2020

57

Selecting Methodologies for the Evaluation of Differences in Time to Response Between Antidepressants

Stuart Montgomery, Per Bech, Pierre Blier,

The Journal of Clinical Psychiatry

2002

44

Frequent and possibly inappropriate use of combination therapy with an oral anticoagulant and antiplatelet agents in patients with atrial fibrillation in Europe

Raffaele De Caterina, Bettina Ammentorp, Harald Darius,

Heart

2014

35

Factors that influence the outcome of placebo-controlled antidepressant clinical trials.

I.A. Niklson, Paul‐Egbert Reimitz, C. Sennef

PubMed

1997

34

Edoxaban in atrial fibrillation patients with percutaneous coronary intervention by acute or chronic coronary syndrome presentation: a pre-specified analysis of the ENTRUST-AF PCI trial

Pascal Vranckx, Marco Valgimigli, Lars Eckardt,

European Heart Journal

2020

29

Page 1